Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,510 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,510 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president owned 29,728 shares in the company, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $366.86 on Thursday. The stock has a market capitalization of $48.47 billion, a PE ratio of 1,528.58 and a beta of 0.32. The company has a 50 day moving average price of $422.03 and a 200-day moving average price of $421.56. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Ameriflex Group Inc. purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $36,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham published a bullish forecast expecting strong price appreciation for ALNY, citing upside from the company’s longer-term growth plan. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: A Yahoo Finance piece examined Alnylam’s valuation in light of the newly unveiled Alnylam 2030 plan — useful context for investors weighing the company’s premium valuation against projected revenue/profitability milestones. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: CEO Yvonne Greenstreet discussed development priorities and the path to profitability in a media interview — helpful for understanding management’s messaging but not new data. Alnylam Pharmaceuticals CEO on development goals, profitability
• Negative Sentiment: Bank of America issued a pessimistic forecast for ALNY, adding downward analyst pressure after the guidance/2030 announcement. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
• Negative Sentiment: Market reaction: a Yahoo report noted ALNY slid sharply after the ambitious 2026 guidance and 2030 plan reveal — indicates investor concern about near-term targets or execution risk. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Multiple insiders (including CEO Yvonne Greenstreet and several EVPs) disclosed sizable stock sales on Jan. 12–13, reducing ownership by ~4–11% in individual cases — typically viewed as a negative signal or a source of additional selling pressure. SEC filing example: SEC filing — Yvonne Greenstreet sale

Analyst Ratings Changes

Several equities research analysts have weighed in on ALNY shares. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. HC Wainwright set a $570.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 4th. Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Finally, Royal Bank Of Canada upped their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $490.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.